All In Biotech

Drug Trial Radar · NCT07633288

A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses

A Randomized, Double-blind, Multicentre, Placebo-controlled, Proof-of-concept Clinical Trial Evaluating the Safety and Efficacy of the Biased Melanocortin Agonist AP1189 Versus Placebo as an add-on to Standard of Care (SOC) in Participants With RESPIRatory Insufficiency Expected to be Caused by Infection With Respiratory Viruses, Including Influenza, Respiratory Syncytial Virus, and Coronavirus

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

Aug 1, 2027

Study completion Aug 1, 2027

Sponsor

Lead sponsor
SynAct Pharma ApsIndustry
Sponsor type
Industry
First posted
Jun 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A clinical study to evaluate the efficacy and safety of once daily oral dosing of 100 mg AP1189 or placebo administered for 14 days, as an add-on to standard of care (SOC) in participants with respiratory insufficiency expected to be caused by respiratory viral infection.

Conditions

  • Respiratory Viral Infection

Interventions

  • AP1189, 100 mgDrug

    14 days of daily treatment of oral AP1189 100 mg as add-on to Standard of Care treatment

  • PlaceboDrug

    14 days of daily treatment of AP1189 matching placebo as add-on to Standard of Care treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants meeting the composite endpoint, consisting of either death, invasive mechanical ventilation, ECMO, cardiovascular organ support, new occurrences of renal failure, hemofiltration or dialysis from baseline to day 28Time frame: 28 days

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • University Clinical Hospital Mostar, Clinic for Infectious Diseases

    Mostar, Herzegovina-Neretva Canton, Bosnia and Herzegovina · Recruiting

  • University Clinical Center Republic of Srpska, Clinic for Infectious Diseases

    Banja Luka, Republika Srpska, Bosnia and Herzegovina · Recruiting

  • University Clinical Centre Sarajevo, Clinic for Infectious Diseases

    Sarajevo, Sarajevo Canton, Bosnia and Herzegovina · Recruiting

  • Clinical Center of Montenegro, Clinic for Infectious Diseases

    Podgorica, Podgorica Municipality, Montenegro · Recruiting

  • Te Toka Tumai Auckland, Auckland City Hospital

    Auckland, New Zealand · Recruiting

  • Aotearoa Clinical Trial Trust, Esme Green Building, Middlemore Hospital

    Auckland, New Zealand · Recruiting

  • Christchurch Hospital, 2 Riccarton Avenue,

    Christchurch, New Zealand · Not yet recruiting

  • MRINZ, 7 CSB Building, Wellington Hospital

    Wellington, New Zealand · Recruiting

  • University Clinical Centre of Serbia, Clinic for Infectious Diseases

    Belgrade, Serbia · Recruiting

  • University Clinical Centre Nis, Clinic for Infectious Diseases

    Niš, Nišava District, Serbia · Recruiting

  • Health Center Uzice, General Hospital Uzice

    Užice, Zlatibor District, Serbia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.